Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
- Design
- Retrospective cohort · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different populationNon-diabetic weight-loss users in US claims data; BMI not available. Closest harm data to a non-diabetic population.
- Could weight loss explain it?
- UnknownHarm outcome; not applicable.
- Study tier
- Study tier 3Observational claims analysis with few events; relative effects are imprecise but directionally consistent with pharmacology and later cohorts.
- Assessment
- Version 5 · Checked against the source by AI · Oct 19, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
A JAMA research letter on gastrointestinal adverse events in people without diabetes using GLP-1 drugs for weight loss, compared with bupropion-naltrexone, using US insurance claims. Its figures are not shown here because they have not been checked against the source.
01Findings
What the study reported
- Drugs
- Semaglutide, Liraglutide
- Comparator
- bupropion-naltrexone
- Primary outcome
- Pancreatitis, gastroparesis, bowel obstruction, biliary disease (claims data, weight-loss indication)
- Effect
- Not checked against the source: the letter has no abstract on file and its full text is not cached.
- 95% confidence interval
- Not extracted
- Follow-up
- Not stated
- Adverse events
- Not extracted
- Limitations
- No abstract in PubMed (JAMA research letter); figures withheld until verified against the full text.
Who was studied
- Obesity status
- prescribed for weight loss (non-diabetic users)
- Diabetes status
- excluded (diabetes users removed)
Study quality details
- Study design
- Retrospective cohort
- Sample size
- not extracted
- Randomization
- no
- Blinding
- not stated
- Comparator
- bupropion-naltrexone
- Follow up duration
- not stated
- Outcome type
- unknown
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- not checked against the source
- Risk of bias
- claims-based ascertainment; active comparator reduces but does not remove confounding
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- Not stated in PubMed metadata (research letter)
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- Academic analysis.
- Author conflicts
- Not available in metadata.
- Independent replication
- partly (VA atlas PMID 39833406 reports pancreatitis signal)
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
No abstract retrieved.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 37796527 first ingestion |